DIAGNOSIS OF RECURRENT BLADDER CANCER BY FLUORESCENCE IN SITU HYBRIDIZATION ASSAY ON URINE SEDIMENT CELLS
https://doi.org/10.17650/1726-9776-2013-9-2-35-41
Abstract
A sample of 63 patients with bladder cancer (BC) was used to estimate the informative value of a noninvasive UroVysion test carried out prior to cystoscopy on urine sediment cells when diagnosing BC recurrences. The latter were detected by either the two techniques (cystoscopy and fluorescence in situ hybridization (FISH) assay) or one of them in 19 patients in different periods after treatment for primary BC (1-36 months). Cystoscopy revealed 13 recurrent BC cases; FISH assay identified 17 cases and in earlier periods. The total sensitivity of the FISH assay was 84.6%. The sample of 20 FISH-positive primary patients showed a direct correlation between BC stage, grade, and the number of abnormal cells (as indicated the UroVysion test) in the urine sediment.
About the Authors
I. E. Vorobtsova
Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, Saint Petersburg
Russian Federation
Russian Federation
Z. Zh. Vasilyeva
Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, Saint Petersburg
Russian Federation
Russian Federation
E. D. Kouzova
Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, Saint Petersburg
Russian Federation
Russian Federation
D. A. Timofeyev
Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, Saint Petersburg
Russian Federation
Russian Federation
M. I. Shkolnik
Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, Saint Petersburg
Russian Federation
Russian Federation
M. V. Odintsova
Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, Saint Petersburg
Russian Federation
Russian Federation
G. M. Zharinov
Russian Research Center for Radiology and Surgical Technologies, Ministry of Health of the Russian Federation, Saint Petersburg
Russian Federation
Russian Federation
References
1. Parekh D.J., Bochner B.H., Dalbagni G. Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessment. J Clin Oncol 2006;24:5519–27.
2. D.A. Levy. Surveillance for Recurrent Bladder Cancer. eMedicine 2008. http:// emedicine.medscape.com/article/458825-overview
3. Hall M.C., Chang S.S., Dalbagni G. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis). J Urol 2007;178(6):2314–30.
4. Halling K.C., King W., Sokolova I.A. et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002;167(5):2001–6.
5. Sokolova I.A., Halling K.C., Jenkins R.B. et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;(3):116–23.
6. Слозина Н.М., Никифоров А.М., Неронов а Е.Г. и др. Молекулярно-цитогенетическая диагностика рака мочевого пузыря. Онкология 2007;8:268–82.
7. Воробцова И.Е., Васильева З.Ж., Школьник М.И. и др. Применение метода флуоресцентной гибридизации in situ на клетках осадка мочи для диагностики рака мочевого пузыря и его рецидивов. Онкоурология 2011;1:73–8.
8. Kipp B.R., Karnes R.J., Brankley S.M. et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005;173:401–4.
9. Воробцова И.Е., Васильева З.Ж. Способ диагностики переходно-клеточного рака мочевого пузыря. Патент РФ №2456607 от 20.07.2012.
10. Halling K.С., King W., Sokolova I.A. et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164(5):1768–75.
11. Башкатов С.В., Севанькаев А.В., Карякин О.Б. и др. Флуоресцентная гибридизация in situ: практическое применение в онкоурологии. Онкоурология 2008;3:9–15.
12. Schrag D., Hsieh L.J., Rabbani F. et al. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 2003;95(8):588–97.
13. Halling K.С. Vysys UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 2003:3(4):507–19.
14. Yoder B.J., Skacel M., Hedgepeth R. et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007;127:295–301.
15. Sokolova I.A., Halling K.C., Jenkins R.B. et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2(3):116–23.
16. Kipp B.R., Tanasescu M., Else T.A. et al. Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer. J Molec Diagn 2009;2;148–54.
Review
For citations:
Vorobtsova I.E., Vasilyeva Z.Zh., Kouzova E.D., Timofeyev D.A., Shkolnik M.I., Odintsova M.V., Zharinov G.M. DIAGNOSIS OF RECURRENT BLADDER CANCER BY FLUORESCENCE IN SITU HYBRIDIZATION ASSAY ON URINE SEDIMENT CELLS. Cancer Urology. 2013;9(2):35-41. (In Russ.) https://doi.org/10.17650/1726-9776-2013-9-2-35-41
Views:
790
Email this article 